Cartesian Therapeutics, Inc.
corporate_fare Company Profile
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for RNAC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for RNAC spans 10-Q, 8-K, DEF 14A, SCHEDULE 13D/A.
Recent high-impact activity:
- Cartesian Posts $0.38 Loss, Beats Estimates by 56 Cents as Net Loss Narrows
- Descartes-08 Retreatment Data Shows 6.6-Point MG-ADL Reduction at Month 12
- Cartesian Q2 2026: Cash Runway to 2028, Phase 3 AURORA Trial Fuels R&D Growth
- Cartesian Therapeutics Reports Q2 Results, Cash Runway Into 2028, and Four Clinical Readouts in Next 12 Months
- Cartesian Partners with WestGene to Advance In Vivo CAR-T Therapies for Autoimmune Diseases
Financial Snapshot
Short Interest & Short Volume
16.50 days to coverFINRA reported short interest of 1,916,302 shares in RNAC as of the October 30, 2026 settlement, a 2.2% increase from the prior period — about 16.5 days to cover at its recent average daily volume. On November 20, 2026, 66.9% of RNAC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.